» Articles » PMID: 34762615

Sedation and Acute Encephalopathy in a Pediatric Patient Following Ingestion of Delta-8-Tetrahydrocannabinol Gummies

Overview
Journal Am J Case Rep
Specialty General Medicine
Date 2021 Nov 11
PMID 34762615
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND Delta-8 tetrahydrocannabinol (delta-8 THC) is an isomer of delta-9-tetrahydrocannabinol (delta-9 THC), the primary psychoactive cannabinoid in the marijuana plant. Typically found at lower concentrations in marijuana, delta-8 THC exhibits psychoactive properties similar to delta-9 THC. Products containing delta-8 THC are readily available across the US and currently there is a lack of available confirmatory testing specific to delta-8 THC as there is cross-reactivity to other naturally occurring cannabinoids in standard immunoassays. Pediatric exposures to this substance are on the rise. CASE REPORT We present a case with laboratory confirmation of a previously healthy 2-year-old girl ingesting approximately 15 mg/kg of delta-8 THC gummies. The patient arrived minimally responsive and requiring intubation for encephalopathy. Laboratory confirmation of delta-8 THC exposure is not routinely available with common testing modalities. A urine drug screen preformed in the hospital was positive for delta-9 THC. With the collaboration of the Drug Enforcement Administration's Toxicology Testing Program, detection and confirmation of delta-8 THC was performed in the serum and urine using liquid chromatography-quadrupole time-of-flight mass spectrometry. CONCLUSIONS The prevalence of delta-8 THC-containing products in the illicit drug market is increasing rapidly. Delta-8 THC products are now available in gas stations and in headshops. The clinical presentation of delta-8 THC exposure is similar to known effects of delta-9 THC exposure. These similarities limit the clinicians' abilities to determine the specific substance ingested. Symptomatic and supportive care remains an effective treatment for cannabinoid toxicity.

Citing Articles

Psychiatric Manifestations of Delta-8-Tetrahydrocannabinol (Δ8-THC) Use Among Patients With Preexisting Psychiatric Disorders: A Case Series.

Singh H, Garg R, Tampi R Cureus. 2025; 17(2):e79621.

PMID: 40008106 PMC: 11853416. DOI: 10.7759/cureus.79621.


Severe Outcomes in Suspected Pediatric Delta-8-THC Exposures.

Ostrowski S, Scanlon M, Barton D, Lynch M, Trautman W J Med Toxicol. 2024; 21(1):89-92.

PMID: 39718684 PMC: 11707218. DOI: 10.1007/s13181-024-01055-4.


Derived psychoactive cannabis product perceptions and use among a sample of US young adults.

LoParco C, Rossheim M, Cui Y, McCready D, Romm K, Wang Y Addict Behav. 2024; 160:108180.

PMID: 39332229 PMC: 11560547. DOI: 10.1016/j.addbeh.2024.108180.


Online Retail of Derived Psychoactive Cannabis Products: Age and Shipping Restrictions.

LoParco C, Tillett K, Berg C, Rossheim M J Adolesc Health. 2024; 75(2):249-253.

PMID: 38864789 PMC: 11257780. DOI: 10.1016/j.jadohealth.2024.05.004.


Asystole in a young child with tetrahydrocannabinol overdose: a case report and review of literature.

Masilamani M, Leff R, Kawai Y Front Toxicol. 2024; 6:1371651.

PMID: 38784384 PMC: 11112079. DOI: 10.3389/ftox.2024.1371651.


References
1.
ElSohly M, Chandra S, Radwan M, Majumdar C, Church J . A Comprehensive Review of Cannabis Potency in the United States in the Last Decade. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021; 6(6):603-606. DOI: 10.1016/j.bpsc.2020.12.016. View

2.
Pertwee R . The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2007; 153(2):199-215. PMC: 2219532. DOI: 10.1038/sj.bjp.0707442. View

3.
Bow E, Rimoldi J . The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation. Perspect Medicin Chem. 2016; 8:17-39. PMC: 4927043. DOI: 10.4137/PMC.S32171. View

4.
Chan-Hosokawa A, Nguyen L, Lattanzio N, Adams W . Emergence of Delta-8 Tetrahydrocannabinol in DUID Investigation Casework: Method Development, Validation and Application. J Anal Toxicol. 2021; 46(1):1-9. DOI: 10.1093/jat/bkab029. View

5.
Grotenhermen F . Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003; 42(4):327-60. DOI: 10.2165/00003088-200342040-00003. View